Improving Vascular Disease Clinical Trial Participation from Black, Latino, Native American Communities with Dr. Jennifer Jones-McMeans Abbott

Dr. Jennifer Jones-McMeans is the Divisional Vice President of Global Clinical Affairs at Abbott's Vascular Business. She talks about recently released data from their Beyond Intervention Survey of 1800 stakeholders including 1289 vascular disease patients, 408 healthcare physicians, and 173 healthcare leaders from across 13 countries. The study looked particularly at Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD) which revealed these diseases disproportionately affect Black, Latino, and Native Americans. Jennifer reports, "I think what Beyond Intervention allowed us to do is to see what the patient is feeling, experiencing, and how does that differ from what your healthcare provider or your healthcare leader is saying? Because one of the key findings that we found was that patient experience is maybe not as good as the healthcare provider may be thinking it is." "And we know that when you look at these social determinants, and they can be anything from socioeconomic status, availability to care, education, impact of income, they all collide. And many times in certain areas, they can collide with race and ethnicity. So when you put people in an environment that is not supportive of health and that you're just reaching so many of the things that I spoke of before, you put them at risk for development of diseases, such as PAD and CAD." @AbbottCardio #ClinicalTrials #VascularDisease #PAD #PeripheralArteryDisease #CAD #CoronaryArteryDisease #SDOH #SocialDeterminantsofHealth Abbott.com Download the transcript here